

Applicant : Solo GOLDSTEIN, Claude GUILLOUNNEAU, Yves
CHARTON, Brian LOCKHART, and Pierre
LESTAGE

Serial No. : 09/888,990

Filed : June 26, 2001

Title : 1,1- and 1,2-Disubstituted Cyclopropane Compounds

Art Unit : 1625

Examiner : Celia CHANG, Esq.

Honorable Commissioner for Patents
PO Box 1450

Alexandria, VA 22313

SUPPLEMENTAL RESPONSE AND AMENDMENT AFTER NOTICE OF APPEAL
UNDER 37 CFR §§ 1.113 AND 1.116

Sir:

Responsive to the Office Action, a Final Rejection, dated 23 September 2003, and
to remove the issues from appeal in the Notice of Appeal filed March 23, 2004.
kindly amend as follows:

IN THE CLAIMS: See Listing of Claims. This listing will replace all prior versions of
claims in the application.

Accordingly, entry of the present amendment, reconsideration of all grounds of
objection and rejection, withdrawal thereof, and passage of this application to issue
are all hereby respectfully solicited.


09/888,990

39

It should be apparent that the undersigned attorney has made an earnest effort to place this application into condition for immediate allowance. If he can be of assistance to the Examiner in the elimination of any possibly-outstanding insignificant impediment to an immediate allowance, the Examiner is respectfully invited to call him at his below-listed number for such purpose.

Allowance is solicited.

Respectfully submitted,
THE FIRM OF HUESCHEN AND SAGE

By: 
G. PATRICK SAGE

Dated: May 27, 2004
Customer No.: 25,666
500 Columbia Plaza
350 East Michigan Ave.
Kalamazoo, MI 49007-3856
(269) 382-0030

Enclosure: Listing of Claims

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

09/888,990

- 1 -

LISTING OF CLAIMS*1-18 (CANCELED)**19-(CURRENTLY AMENDED) A compound selected from those of formula (I) :*

5

wherein :

p represents an integer of from 0 to 6 inclusive,

n represents an integer of from 0 to 6 inclusive,

R₁ and R₂, which may be identical or different, each independently of the other represent a group selected from hydrogen, linear or branched (C₁-C₆)alkyl, aryl, and aryl-(C₁-C₆)alkyl in which alkyl is linear or branched,

X represents a group selected from oxygen, sulphur,

Y represents a group selected from pyridyl, and

its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base,

15

it also being understood that :

- aryl denotes phenyl, biphenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, or indenyl, each of those groups being optionally substituted by one or more, identical or different, groups selected from halogen, linear or branched (C₁-C₆)alkyl, hydroxy, cyano, nitro, linear or branched (C₁-C₆)alkoxy, linear or branched (C₂-C₇)acyl, linear or branched (C₁-C₆)alkoxycarbonyl, linear or branched (C₁-C₆)trihaloalkyl, linear or branched (C₁-C₆)tribromoalkoxy, and amino optionally substituted by one or two linear or branched (C₁-C₆)alkyl,

20

- pyridyl denotes a pyridyl group which is optionally substituted by one or more, identical or different, groups selected from substituents defined hereinbefore for aryl.

25

20-(PREVIOUSLY PRESENTED) A compound of claim 19, wherein n is an integer of from 0 to 2 inclusive.

- 2 -


3 21-(PREVIOUSLY PRESENTED) A compound of claim 19, wherein R₁ and R₂, which may be identical or different, each represent hydrogen, or linear or branched (C₁-C₆)alkyl.

4 22-(PREVIOUSLY PRESENTED) A compound of claim 19, wherein X represents oxygen.

5 23-(CANCELED)


24-(CANCELED)

5 25-(PREVIOUSLY PRESENTED) A compound of claim 19, which is a compound of formula (IA) :



10 wherein n, p, X, Y, R₁ and R₂ are as defined for formula (I), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

6 26-(PREVIOUSLY PRESENTED) A compound of claim 19, which is a compound of formula (IB) :



15 wherein n, p, X, Y, R₁, and R₂ are as defined for formula (I), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

7 27-(PREVIOUSLY PRESENTED) A compound of claim 19, wherein p is an integer having the value 0 or 1.

8 28-(PREVIOUSLY PRESENTED) A compound of claim 26, wherein p represents 0, or

- 3 -

1, n represents 0, or 1, R₁ and R₂, which may be identical or different, represent hydrogen, or linear or branched (C₁-C₆)alkyl, X represents oxygen, and Y represents pyridyl, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

5

9 29- (PREVIOUSLY PRESENTED) A compound of claim 28, wherein p represents 0, or 5 n is an integer of from 0 to 3 inclusive, R₁ and R₂, which may be identical or different, represent hydrogen, linear or branched (C₁-C₆)alkyl, X represents oxygen or sulphur and Y represents pyridyl, (pyridyl being optionally substituted by a group selected from halogen, and linear or branched (C₁-C₆)alkyl), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

10

10 30- (PREVIOUSLY PRESENTED) A compound of claim 19, which is selected from :

- N,N-dimethyl-1-[(3-pyridyloxy)methyl]cyclopropanamine,
- N-methyl-1-[(3-pyridyloxy)methyl]cyclopropanamine,
- N,N-dimethyl-1-[(3-pyridylmethoxy)methyl]cyclopropanamine,
- N,N-dimethyl-1-[2-(3-pyridyloxy)ethyl]cyclopropanamine,
- 15 ▪ 1-[(3-pyridyloxy)methyl]cyclopropanamine dihydrochloride,
- N-methyl-1-{{[(6-methyl-3-pyridyl)oxy]methyl}cyclopropanamine hydrochloride,
- N-methyl-1-{{[(6-chloro-3-pyridyl)oxy]methyl}cyclopropanamine hydrochloride,
- N-methyl-1-[(2-pyridylsulphonyl)methyl]cyclopropanamine dihydrochloride,
- N-methyl-1-[3-(3-pyridyloxy)propyl]cyclopropanamine dihydrochloride, and
- 20 ▪ N-methyl-1-[2-(3-pyridyloxy)ethyl]cyclopropanamine fumarate,

its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

31- (CANCELED)

32- (CANCELED)

12 33- (CURRENTLY AMENDED) A method for treating pain and memory or cognitive 25 deficiency in a living animal body afflicted with age related cognitive disorders and neurodegenerative disorders selected from Tourett's Syndrome, Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, frontal lobe and subcortical

- 4 -

dementias, ~~hyperactivity syndrome with attention-deficit disorder, tobacco withdrawal, pain, and mood disorders~~, comprising the step of administering to the living animal body an amount of a compound of claim 19 which is effective for alleviation of said conditions.

11 34- (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising as active
5 principle an effective amount of a compound as claimed in claim 19, alone or in combination with one or more pharmaceutically-acceptable excipients or carriers.

35- (CANCELED)

36- (CANCELED)

Serial No. 09/888,990
Supplemental Response and Amendment After Notice of Appeal of May 27, 2004
SERVIER 359